T. Herrmann

Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study

A. Ginzac, X. Durando, I. Molnar, 2021, Cancer medicine.

Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma

A. Ginzac, X. Durando, I. Molnar, 2021, Oncology.

Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16.

L. Cardon, C. Mathew, J. Hampe, 1998, Gastroenterology.

Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab

X. Durando, T. Herrmann, Nathan El-ghazzi, 2023, OncoTargets and therapy.

Analysis of single-nucleotide polymorphisms in the interleukin-4 receptor gene for association with inflammatory bowel disease

S. Schreiber, D. F. Easton, D. Teare, 2000, Immunogenetics.

Accelerated hyperfractionated radiation therapy to 70.6 Gy plus 5-FU/MMC (C-HART) is more effective than HART to 77.6 Gy alone for locally advanced head and neck cancer. Four-year results of the German ARO 95-6 trial in 384 patients

P. Wust, V. Budach, K. Wernecke, 2003 .

Mutation of Tp53 in a Patient with Aggressive Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma

A. Ginzac, X. Durando, F. Mishellany, 2020 .